Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing
Colorectal cancer (CRC) is the third most common cancer in the world. Despite improvement in standardized screening methods and the development of promising therapies, the 5-year survival rates are as low as 10% in the metastatic setting. The increasing life expectancy of the general population, hig...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/9/2105 |
| _version_ | 1797505455720759296 |
|---|---|
| author | Talal El Zarif Marcel Yibirin Diana De Oliveira-Gomes Marc Machaalani Rashad Nawfal Gianfranco Bittar Hisham F. Bahmad Nizar Bitar |
| author_facet | Talal El Zarif Marcel Yibirin Diana De Oliveira-Gomes Marc Machaalani Rashad Nawfal Gianfranco Bittar Hisham F. Bahmad Nizar Bitar |
| author_sort | Talal El Zarif |
| collection | DOAJ |
| description | Colorectal cancer (CRC) is the third most common cancer in the world. Despite improvement in standardized screening methods and the development of promising therapies, the 5-year survival rates are as low as 10% in the metastatic setting. The increasing life expectancy of the general population, higher rates of obesity, poor diet, and comorbidities contribute to the increasing trends in incidence. Drug repurposing offers an affordable solution to achieve new indications for previously approved drugs that could play a protagonist or adjuvant role in the treatment of CRC with the advantage of treating underlying comorbidities and decreasing chemotherapy toxicity. This review elaborates on the current data that supports drug repurposing as a feasible option for patients with CRC with a focus on the evidence and mechanism of action promising repurposed candidates that are widely used, including but not limited to anti-malarial, anti-helminthic, anti-inflammatory, anti-hypertensive, anti-hyperlipidemic, and anti-diabetic agents. |
| first_indexed | 2024-03-10T04:18:50Z |
| format | Article |
| id | doaj.art-424d9309320b455fb128dae44b6adbb6 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T04:18:50Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-424d9309320b455fb128dae44b6adbb62023-11-23T07:54:56ZengMDPI AGCancers2072-66942022-04-01149210510.3390/cancers14092105Overcoming Therapy Resistance in Colon Cancer by Drug RepurposingTalal El Zarif0Marcel Yibirin1Diana De Oliveira-Gomes2Marc Machaalani3Rashad Nawfal4Gianfranco Bittar5Hisham F. Bahmad6Nizar Bitar7Faculty of Medicine, Lebanese University, Beirut 1003, LebanonInternal Medicine Residency Program, Department of Medicine, Boston University Medical Center, Boston, MA 02218, USADepartment of Research, Foundation for Clinic, Public Health, and Epidemiological Research of Venezuela (FISPEVEN), Caracas 1050, VenezuelaFaculty of Medicine, Lebanese University, Beirut 1003, LebanonFaculty of Medicine, Lebanese University, Beirut 1003, LebanonBaylor St. Luke’s Medical Center, Houston, TX 770030, USAThe Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USAHead of Hematology-Oncology Division, Sahel General Hospital, Beirut 1002, LebanonColorectal cancer (CRC) is the third most common cancer in the world. Despite improvement in standardized screening methods and the development of promising therapies, the 5-year survival rates are as low as 10% in the metastatic setting. The increasing life expectancy of the general population, higher rates of obesity, poor diet, and comorbidities contribute to the increasing trends in incidence. Drug repurposing offers an affordable solution to achieve new indications for previously approved drugs that could play a protagonist or adjuvant role in the treatment of CRC with the advantage of treating underlying comorbidities and decreasing chemotherapy toxicity. This review elaborates on the current data that supports drug repurposing as a feasible option for patients with CRC with a focus on the evidence and mechanism of action promising repurposed candidates that are widely used, including but not limited to anti-malarial, anti-helminthic, anti-inflammatory, anti-hypertensive, anti-hyperlipidemic, and anti-diabetic agents.https://www.mdpi.com/2072-6694/14/9/2105colorectal cancertherapy resistancedrug repurposingin silico drug screens |
| spellingShingle | Talal El Zarif Marcel Yibirin Diana De Oliveira-Gomes Marc Machaalani Rashad Nawfal Gianfranco Bittar Hisham F. Bahmad Nizar Bitar Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing Cancers colorectal cancer therapy resistance drug repurposing in silico drug screens |
| title | Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing |
| title_full | Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing |
| title_fullStr | Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing |
| title_full_unstemmed | Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing |
| title_short | Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing |
| title_sort | overcoming therapy resistance in colon cancer by drug repurposing |
| topic | colorectal cancer therapy resistance drug repurposing in silico drug screens |
| url | https://www.mdpi.com/2072-6694/14/9/2105 |
| work_keys_str_mv | AT talalelzarif overcomingtherapyresistanceincoloncancerbydrugrepurposing AT marcelyibirin overcomingtherapyresistanceincoloncancerbydrugrepurposing AT dianadeoliveiragomes overcomingtherapyresistanceincoloncancerbydrugrepurposing AT marcmachaalani overcomingtherapyresistanceincoloncancerbydrugrepurposing AT rashadnawfal overcomingtherapyresistanceincoloncancerbydrugrepurposing AT gianfrancobittar overcomingtherapyresistanceincoloncancerbydrugrepurposing AT hishamfbahmad overcomingtherapyresistanceincoloncancerbydrugrepurposing AT nizarbitar overcomingtherapyresistanceincoloncancerbydrugrepurposing |